E2F6 Polyclonal antibody

• 

  WB analysis using 10691-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10691-1-AP (E2F6 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

E2F6 Polyclonal Antibody for WB, ELISA

Cat No. 10691-1-AP

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Synonyms

E2F-6, E2F 6

---

Tested Applications

• Positive WB detected in: A549 cells, HepG2 cells, HuH-7 cells, K-562 cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

10691-1-AP targets E2F6 in WB, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: E2F6 fusion protein Ag1029
• Full Name: E2F transcription factor 6
• Calculated Molecular Weight: 32 kDa
• Observed Molecular Weight: 37 kDa
• GenBank Accession Number: BC008348
• Gene Symbol: E2F6
• Gene ID (NCBI): 1876
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• UNIPROT ID: O75461
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol , pH 7.3
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

E2F6 is a member of the E2F family of transcription factors, which play important roles in cell cycle regulation and gene expression. E2F6 is highly expressed in many types of cancer and is associated with poor prognosis. It is involved in the regulation of cell proliferation and can promote tumor growth. E2F6 knockdown significantly reduces the proliferative ability of glioma cells (PMID: 38071912). Additionally, E2F6 is related to immune activation markers, tumor immune cell infiltration, and immune regulators, making it a potential biomarker for predicting the response to cancer immunotherapy.